Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
55.05 (1y: +61%)
Market Cap 144.39 B P/E(ttm) 27.40
Enterprise Value 154.66 B P/B 2.00
SNY- NYSE (USA)
Sanofi
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$55.05
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 0.451
SNY's Cash to Debt is ranked lower than
82% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.36 vs. SNY: 0.451 )
SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: 10.62
Current: 0.45
0.14
10.62
Equity to Asset -0.009
SNY's Equity to Asset is ranked lower than
93% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.52 vs. SNY: -0.009 )
SNY' s 10-Year Equity to Asset Range
Min: -0.23   Max: 0.54
Current: -0.01
-0.23
0.54
Interest Coverage 13.8
SNY's Interest Coverage is ranked lower than
79% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10000.00 vs. SNY: 13.8 )
SNY' s 10-Year Interest Coverage Range
Min: 14   Max: No Debt
Current: 13.8
Z-Score: 2
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 17.60
SNY's Operating margin (%) is ranked higher than
60% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.70 vs. SNY: 17.60 )
SNY' s 10-Year Operating margin (%) Range
Min: -2   Max: 38.2
Current: 17.6
-2
38.2
Net-margin (%) 13.8
SNY's Net-margin (%) is ranked higher than
81% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. SNY: 13.8 )
SNY' s 10-Year Net-margin (%) Range
Min: -24   Max: 25.8
Current: 13.8
-24
25.8
ROE (%) 8.7
SNY's ROE (%) is ranked higher than
68% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. SNY: 8.7 )
SNY' s 10-Year ROE (%) Range
Min: -10.1   Max: 32.8
Current: 8.7
-10.1
32.8
ROA (%) 4.9
SNY's ROA (%) is ranked higher than
61% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. SNY: 4.9 )
SNY' s 10-Year ROA (%) Range
Min: -4.7   Max: 21.3
Current: 4.9
-4.7
21.3
ROC (Joel Greenblatt) (%) 37.80
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.40 vs. SNY: 37.80 )
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3   Max: 111.4
Current: 37.8
-3
111.4
Revenue Growth (%) 3.5
SNY's Revenue Growth (%) is ranked higher than
84% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. SNY: 3.5 )
SNY' s 10-Year Revenue Growth (%) Range
Min: 1   Max: 19.9
Current: 3.5
1
19.9
EBITDA Growth (%) -0.7
SNY's EBITDA Growth (%) is ranked higher than
86% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.35 vs. SNY: -0.7 )
SNY' s 10-Year EBITDA Growth (%) Range
Min: -7.6   Max: 34.4
Current: -0.7
-7.6
34.4
EPS Growth (%) -1.8
SNY's EPS Growth (%) is ranked higher than
78% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. SNY: -1.8 )
SNY' s 10-Year EPS Growth (%) Range
Min: -8.8   Max: 29.9
Current: -1.8
-8.8
29.9
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

SNY Guru Trades in Q2 2012

Manning & Napier Advisors, Inc 234,565 sh (+184.87%)
John Hussman 27,100 sh (+22.62%)
Whitney Tilson 65,000 sh (+18.18%)
Zeke Ashton 75,000 sh (+15.38%)
David Dreman 102,914 sh (+12.56%)
HOTCHKIS & WILEY 4,571,262 sh (+7.4%)
NWQ Managers 13,631,387 sh (+0.48%)
PRIMECAP Management 2,223,692 sh (+0.04%)
Murray Stahl 29,000 sh (unchged)
Warren Buffett 4,063,675 sh (unchged)
Jean-Marie Eveillard 808,762 sh (unchged)
Francis Chou 410,000 sh (unchged)
Steven Cohen Sold Out
Ken Fisher 14,365,886 sh (-1.23%)
Dodge & Cox 48,554,120 sh (-2.28%)
James Barrow 4,610,275 sh (-2.52%)
Third Avenue Management 17,385 sh (-4.53%)
Charles Brandes 3,996,734 sh (-7.86%)
» More
Q3 2012

SNY Guru Trades in Q3 2012

Sarah Ketterer 49,576 sh (New)
Steven Cohen 99,697 sh (New)
Manning & Napier Advisors, Inc 253,273 sh (+7.98%)
James Barrow 4,710,615 sh (+2.18%)
HOTCHKIS & WILEY 4,646,066 sh (+1.64%)
Murray Stahl 29,000 sh (unchged)
Warren Buffett 4,063,675 sh (unchged)
Jean-Marie Eveillard 808,762 sh (unchged)
Francis Chou 410,000 sh (unchged)
John Hussman 27,100 sh (unchged)
David Dreman Sold Out
PRIMECAP Management 2,206,592 sh (-0.77%)
Dodge & Cox 47,686,485 sh (-1.79%)
Ken Fisher 13,970,779 sh (-2.75%)
NWQ Managers 12,962,969 sh (-4.9%)
Zeke Ashton 65,000 sh (-13.33%)
Whitney Tilson 52,500 sh (-19.23%)
Charles Brandes 2,982,819 sh (-25.37%)
Third Avenue Management 12,785 sh (-26.46%)
» More
Q4 2012

SNY Guru Trades in Q4 2012

Sarah Ketterer 67,294 sh (+35.74%)
Third Avenue Management 12,785 sh (unchged)
Warren Buffett 4,063,675 sh (unchged)
Francis Chou 410,000 sh (unchged)
Jean-Marie Eveillard 808,762 sh (unchged)
Zeke Ashton Sold Out
Whitney Tilson Sold Out
Steven Cohen Sold Out
Manning & Napier Advisors, Inc 252,654 sh (-0.24%)
James Barrow 4,685,593 sh (-0.53%)
PRIMECAP Management 2,165,992 sh (-1.84%)
Dodge & Cox 46,238,268 sh (-3.04%)
Ken Fisher 13,177,622 sh (-5.68%)
Murray Stahl 27,000 sh (-6.9%)
HOTCHKIS & WILEY 4,108,228 sh (-11.58%)
NWQ Managers 11,144,845 sh (-14.03%)
Charles Brandes 2,458,811 sh (-17.57%)
John Hussman 22,100 sh (-18.45%)
» More
Q1 2013

SNY Guru Trades in Q1 2013

James Barrow 5,417,861 sh (+15.63%)
Sarah Ketterer 77,131 sh (+14.62%)
HOTCHKIS & WILEY 4,578,740 sh (+11.45%)
Manning & Napier Advisors, Inc 275,034 sh (+8.86%)
Francis Chou 410,000 sh (unchged)
John Hussman 22,100 sh (unchged)
Jean-Marie Eveillard 808,762 sh (unchged)
Warren Buffett 4,063,675 sh (unchged)
PRIMECAP Management 2,123,431 sh (-1.96%)
Third Avenue Management 12,485 sh (-2.35%)
Ken Fisher 12,857,867 sh (-2.43%)
Dodge & Cox 44,670,455 sh (-3.39%)
Murray Stahl 26,000 sh (-3.7%)
Charles Brandes 2,150,989 sh (-12.52%)
NWQ Managers 8,381,844 sh (-24.79%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2012-09-30 Reduce -25.37%0.41%$36.81 - $44.6 $ 55.0536%2982819
David Dreman 2012-09-30 Sold Out 0.09%$36.81 - $44.6 $ 55.0536%0
John Hussman 2012-06-30 Add 22.62%$33.4 - $39.06 $ 55.0553%27100
PRIMECAP Management 2012-03-31 Add 141.26%0.08%$35.32 - $38.92 $ 55.0557%2222692
George Soros 2011-12-31 Sold Out 0.11%$31.72 - $37.45 $ 55.0560%0
James Barrow 2011-12-31 Add 26.83%0.08%$31.72 - $37.45 $ 55.0560%4501475
James Barrow 2011-09-30 Add 83.96%0.13%$31.5 - $40.08 $ 55.0553%3549200
George Soros 2011-09-30 New Buy0.11%$31.5 - $40.08 $ 55.0553%201400
Dodge & Cox 2011-06-30 Add 6.63%0.16%$35.68 - $40.58 $ 55.0545%54287695
James Barrow 2011-06-30 Add 43.65%0.05%$35.68 - $40.58 $ 55.0545%1929300
David Dreman 2011-06-30 Add 38.36%0.02%$35.68 - $40.58 $ 55.0545%96767
John Hussman 2011-06-30 Add 39.68%$35.68 - $40.58 $ 55.0545%17600
Dodge & Cox 2011-03-31 Add 6.45%0.12%$31.87 - $36.2 $ 55.0561%50912344
James Barrow 2011-03-31 New Buy0.1%$31.87 - $36.2 $ 55.0561%1343100
David Dreman 2011-03-31 Add 34.03%0.01%$31.87 - $36.2 $ 55.0561%69940
John Hussman 2010-12-31 Add 215%0.01%$30.52 - $36.31 $ 55.0564%12600
Dodge & Cox 2010-06-30 Add 38.73%0.56%$28.47 - $37.49 $ 55.0569%48592109
David Dreman 2010-06-30 New Buy0.03%$28.47 - $37.49 $ 55.0569%37356
Warren Buffett 2010-06-30 Add 4.09%0.01%$28.47 - $37.49 $ 55.0569%4063675
John Hussman 2010-06-30 New Buy$28.47 - $37.49 $ 55.0569%4000
Charles Brandes 2010-03-31 Reduce -20.84%0.33%$35.51 - $41.55 $ 55.0545%7758240
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 27.40
SNY's P/E(ttm) is ranked higher than
77% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.76 vs. SNY: 27.40 )
SNY' s 10-Year P/E(ttm) Range
Min: 9.65   Max: 176.2
Current: 27.4
9.65
176.2
P/B 2.00
SNY's P/B is ranked higher than
75% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. SNY: 2.00 )
SNY' s 10-Year P/B Range
Min: 1.12   Max: 7.05
Current: 2
1.12
7.05
P/S 3.23
SNY's P/S is ranked lower than
54% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. SNY: 3.23 )
SNY' s 10-Year P/S Range
Min: 1.77   Max: 5.42
Current: 3.23
1.77
5.42
PFCF 17.40
SNY's PFCF is ranked higher than
89% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. SNY: 17.40 )
SNY' s 10-Year PFCF Range
Min: 6.66   Max: 146.89
Current: 17.4
6.66
146.89
EV-to-EBIT 22.2
SNY's EV-to-EBIT is ranked higher than
64% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.70 vs. SNY: 22.2 )
SNY' s 10-Year EV-to-EBIT Range
Min: 10.5   Max: 204.2
Current: 22.2
10.5
204.2
PEG 24.8
SNY's PEG is ranked lower than
78% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. SNY: 24.8 )
SNY' s 10-Year PEG Range
Min: 0.27   Max: 24.8
Current: 24.8
0.27
24.8
Shiller P/E 22.7
SNY's Shiller P/E is ranked lower than
78% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.12 vs. SNY: 22.7 )
SNY' s 10-Year Shiller P/E Range
Min: 13.35   Max: 23.57
Current: 22.7
13.35
23.57

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.37
SNY's Dividend Yield is ranked higher than
96% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. SNY: 2.37 )
SNY' s 10-Year Dividend Yield Range
Min: 1.21   Max: 5.46
Current: 2.37
1.21
5.46
Dividend Payout 0.8153
SNY's Dividend Payout is ranked higher than
58% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.86 vs. SNY: 0.8153 )
SNY' s 10-Year Dividend Payout Range
Min: 0.27   Max: 0.72
Current: 0.82
0.27
0.72
Dividend growth (3y) 4.8
SNY's Dividend growth (3y) is ranked higher than
91% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.95 vs. SNY: 4.8 )
SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 16.1
Current: 4.8
0
16.1
Yield on cost (5-Year) 3.27
SNY's Yield on cost (5-Year) is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. SNY: 3.27 )
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.65   Max: 7.45
Current: 3.27
1.65
7.45
Share Buyback Rate -0.4
SNY's Share Buyback Rate is ranked higher than
85% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.00 vs. SNY: -0.4 )
SNY' s 10-Year Share Buyback Rate Range
Min: 1   Max: -17.9
Current: -0.4

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 13.1
SNY's Price/Net Current Asset Value is ranked higher than
68% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. SNY: 13.1 )
SNY' s 10-Year Price/Net Current Asset Value Range
Min: 8.3   Max: 40.1
Current: 13.1
8.3
40.1
Price/DCF (Projected) 1.5
SNY's Price/DCF (Projected) is ranked lower than
76% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. SNY: 1.5 )
SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 0.8
Current: 1.5
0.6
0.8
Price/Median PS Value 1.2
SNY's Price/Median PS Value is ranked higher than
87% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.70 vs. SNY: 1.2 )
SNY' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.9
Current: 1.2
0.7
1.9
Price/Peter Lynch Fair Value 2.9
SNY's Price/Peter Lynch Fair Value is ranked lower than
73% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. SNY: 2.9 )
SNY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 2.1
Current: 2.9
0.6
2.1
Earnings Yield (Greenblatt) 4.50
SNY's Earnings Yield (Greenblatt) is ranked lower than
77% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. SNY: 4.50 )
SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9.5
Current: 4.5
0.5
9.5
Forward Rate of Return (Yacktman) 14.82
SNY's Forward Rate of Return (Yacktman) is ranked lower than
82% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.82 vs. SNY: 14.82 )
SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 11.5   Max: 51.6
Current: 14.82
11.5
51.6

Business Description

Sanofi was founded in 1970. It is a global healthcare Company engaged in offering solutions across areas of core historical strength and multiple growth platforms. Within its Pharmaceuticals business, it focuses on various areas which include diabetes, rare diseases, oncology, and other flagship products in anti-thrombotics, cardiovascular, renal and biosurgery fields. The Company is facing competition from generics for several of its major products, in an environment subject to cost containment pressures from both third party payers and healthcare authorities. The manufacturing and research operations of the Company is subject to increasingly stringent health, safety and environmental (HSE) laws and regulations.
Company Website
Industry: Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS
Traded in other countries:SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial